Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Invesco DB Commodity Index Tracking Fund (DBC) vs Cassava Sciences Inc (FLNA) Price & Performance

Invesco DB Commodity Index Tracking FundTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Invesco DB Commodity Index Tracking Fund vs Cassava Sciences Inc — how do they compare? Invesco DB Commodity Index Tracking Fund trades at $28.58, while Cassava Sciences Inc trades at $1.11 (market cap $52.66M). The key difference: Invesco DB Commodity Index Tracking Fund is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

DBCFLNA
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$31.69$4.64
52-Week Low
$21.62$1.09
Market Cap
$52.66M
Enterprise Value
-$33.92M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Invesco DB Commodity Index Tracking Fund

DBC, the Invesco DB Commodity Index Tracking ETF, trades at $28.33, up 2.94% today, with a bullish technical signal from moving averages and oscillators. Recent news highlights its role as an inflation hedge, with a 52-week high noted in April 2026. The ETF provides diversified commodity exposure, benefiting from oil supply shocks and safe-haven demand, though key financial ratios like P/E and P/S are not applicable for this fund structure.

Outlook remains positive due to strong momentum and inflation hedging appeal, but risks include commodity price volatility and geopolitical factors. Analyst sentiment is supportive, with the ETF favored in balanced portfolios for moderate-risk investors seeking commodity diversification amid market uncertainty.

Cassava Sciences Inc

FLNA trades at $1.15, down 2.54% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company continues to report losses, with a net income of -$90.97M in 2025 and negative cash flow, though it has beaten EPS estimates for the last three quarters. Recent news highlights ongoing development in its TSC-related epilepsy therapies.

Despite consistent earnings beats, FLNA's negative profitability and cash burn pose significant risks. Analyst sentiment is positive with a 66.7% buy rating, but the stock's outlook depends heavily on clinical success and future funding. Investors should weigh the high-risk, high-reward nature of this biotech play.

Returns comparison

Trailing returns across standard periods

About Invesco DB Commodity Index Tracking Fund

DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.

Read more on DBC

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA